University Research Park (URP), University of Wisconsin Madison, Research and Technology Park, Early Stage Incubator, Technology Transfer, Tech Transfer, Research Parks

Home | Contact Us

University Research Park to add second technology "accelerator"
March 12, 2008 - MADISON, Wis.University Research Park has announced plans to build a new, 65,000-square-foot “accelerator building” to house life-science companies that have moved beyond early-stage development.

...............................................

University Research Park publishes "The First Fifteen Years: 1984-1999", a retrospective about the award winning research park
March 7, 2008 - MADISON, Wis.
The publication, written by Arthur Hove leads readers through the park's first 15 years, spotlighting the innovative efforts that brought the park from idea to reality.

Wisconsin's sights are set on Earth-friendly tourism
USA Today | September 07
The Aldo Leopold Legacy Center is just one example of some 100 lodgings, restaurants, attractions and other tourism-related businesses to be certified by Travel Green Wisconsin, a statewide initiative launched earlier this year that's the first of its kind in the USA.

25 Best Cities: Kiplinger / Richard Florida Rankings
June 2007
Madison is picked as one of top 25 cities with a large creative class—a population that fuels cultural and economic vitality—that are suited for people in different life stages.

Country Home Magazine Study Ranks Madison one of the top Eco-Friendly Cities and Towns
April 2007
In a study conducted by Country Home Magazine, Madison was rated one of the ten most eco-friendly cities in the United States in which to live.

Stemina Biomarker Discovery, Inc.
Stemina’s innovative cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics. As a result, Stemina discovers and validates small molecules as biomarkers for high throughput drug screening and disease diagnostics in an all human system.

Quintessence Biosciences, Inc.
Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.